Get our news
For up-to-date company news delivered straight to your inbox or phone, sign up for Investor Alerts today.
Topical treatment of atopic dermatitis (eczema).
JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs.
A Phase 3, double-blind, placebo-controlled multi-center trial is underway to evaluate the superiority of JW-100 to Eucrisa (an FDA-approved topical drug) in mild-to-moderate eczema.
JW-100 is pre-revenue.
Market analysis and go-to-market plans are being developed with an anticipated product launch in 2023.
To receive alerts via text message, send JUPW to
+1 (844) 819-8138